Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (16591)	2/10/2004 1:23:26 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George, how many in the Raptiva trials have been treated for over a year???? I thought you didn't like the FDA???? What do you want them to do require 10,000 people to be on a Biological for at least five years in Phase III so they can say you can take it with their blessing continuously for over a year???? Look at ANY chronic administered medication that is approved in the beginning. I guess you MISSED the good news that with this carrier Raptiva is considered medically necessary(which means they will gladly pay for it!!!!) under their guidelines WITH THE UNDERSTANDING AT THIS TIME WHO KNOWS WHAT WILL HAPPEN IN LARGE AMOUNTS OF PEOPLE AFTER MANY YEARS OF CONTINUOUS TREATMENT. Kinda like LYMPHOMAS popping up in patients taking ENBREL. Once again go to ANY search engine and put in ENBREL LAWSUITS!!!!!